Objective:To analyze the effects of entecavir on tear secretion and tear film function in patients with hepatitis B virus (HBV) infection.Methods:A retrospective analysis was conducted on the clinical data of 24 patients with HBV infection who received treatment with entecavir at the Department of Ophthalmology, Affiliated Hospital of Shaoxing University from April to October 2022. The relevant examination results of dry eye in these patients were analyzed before medication and at 1 and 3 months after medication.Results:Before medication, 13 cases (54.17%) had dry eye, and 3 months after medication, 17 cases (70.83%) had dry eye. At 1 and 3 months after treatment with entecavir, the Ocular Surface Disease Index values of the patients were (13.83 ± 7.11) points and (15.29 ± 6.94) points, respectively. There was no significant difference in Ocular Surface Disease Index value between before and after treatment ( t = -0.24, -1.24, both P>0.05). At 1 and 3 months after treatment, the Schirmer I test results were (8.74 ± 2.40) mm and (8.21 ± 2.40) mm, respectively. The Schirmer I test results at 3 months after treatment were significantly lower than those before treatment ( t = 2.12, P<0.05). At 3 months after treatment, the tear film break-up time was reduced to (7.63 ± 1.97) seconds, which was significantly shorter than the value recorded before treatment ( t = 2.12, P<0.05). At 3 months after treatment, the height of the tear meniscus was (0.21 ± 0.06) mm, which was significantly different from that measured before treatment ( t = 2.26, P<0.05).At 3 months after treatment, the red eye index increased compared with the value recorded before treatment, but the difference was not statistically significant ( t = -0.35, -0.94, both P>0.05). Conclusions:Patients with HBV infection are prone to developing dry eye syndrome. After treatment with entecavir, there may be a reduction in tear secretion and a decline in tear film function, which should be a concern for clinicians.

Objective:To investigate the effects of vitreomacular traction (VMT) on the efficacy of internal limiting membrane (ILM) removal combined with air tamponade in the treatment of macular holes.Methods:The clinical data of 44 patients with macular holes who underwent ILM removal combined with air tamponade at the Affiliated Hospital of Shaoxing University from January 2019 to December 2022 were collected and analyzed retrospectively. The patients were divided into two groups based on the presence of VMT prior to surgery: the VMT group and the non-VMT group, with 22 cases in each group. The best corrected visual acuity, closure of the macular hole, continuity of the external limiting membrane, and ellipsoid zone integrity were compared between the two groups during the postoperative follow-up.Results:There was no significant difference in the best corrected visual acuity, the rate of visual acuity improvement, or the rate of macular hole closure between the two groups (all P > 0.05). However, the continuity rate of the external limiting membrane [54.5% (12/22)] and the rate of ellipsoid band integrity [36.4% (8/22)] in the VTM group were significantly higher than those in the non-VTM group [9.1% (2/22), 0; χ2 = 10.47, 7.49, both P < 0.05]. Conclusions:Macular holes caused by VMT show better outcomes after vitrectomy to relieve the vitreous traction. However, for macular holes without remarkable VMT, vitrectomy alone may not yield ideal results. In such cases, it may be necessary to expand the area of ILM removal to adequately relieve the tangential traction.

Objective:To analyze the effects of entecavir on tear secretion and tear film function in patients with hepatitis B virus (HBV) infection.Methods:A retrospective analysis was conducted on the clinical data of 24 patients with HBV infection who received treatment with entecavir at the Department of Ophthalmology, Affiliated Hospital of Shaoxing University from April to October 2022. The relevant examination results of dry eye in these patients were analyzed before medication and at 1 and 3 months after medication.Results:Before medication, 13 cases (54.17%) had dry eye, and 3 months after medication, 17 cases (70.83%) had dry eye. At 1 and 3 months after treatment with entecavir, the Ocular Surface Disease Index values of the patients were (13.83 ± 7.11) points and (15.29 ± 6.94) points, respectively. There was no significant difference in Ocular Surface Disease Index value between before and after treatment ( t = -0.24, -1.24, both P>0.05). At 1 and 3 months after treatment, the Schirmer I test results were (8.74 ± 2.40) mm and (8.21 ± 2.40) mm, respectively. The Schirmer I test results at 3 months after treatment were significantly lower than those before treatment ( t = 2.12, P<0.05). At 3 months after treatment, the tear film break-up time was reduced to (7.63 ± 1.97) seconds, which was significantly shorter than the value recorded before treatment ( t = 2.12, P<0.05). At 3 months after treatment, the height of the tear meniscus was (0.21 ± 0.06) mm, which was significantly different from that measured before treatment ( t = 2.26, P<0.05).At 3 months after treatment, the red eye index increased compared with the value recorded before treatment, but the difference was not statistically significant ( t = -0.35, -0.94, both P>0.05). Conclusions:Patients with HBV infection are prone to developing dry eye syndrome. After treatment with entecavir, there may be a reduction in tear secretion and a decline in tear film function, which should be a concern for clinicians.

Objective:To investigate the effects of vitreomacular traction (VMT) on the efficacy of internal limiting membrane (ILM) removal combined with air tamponade in the treatment of macular holes.Methods:The clinical data of 44 patients with macular holes who underwent ILM removal combined with air tamponade at the Affiliated Hospital of Shaoxing University from January 2019 to December 2022 were collected and analyzed retrospectively. The patients were divided into two groups based on the presence of VMT prior to surgery: the VMT group and the non-VMT group, with 22 cases in each group. The best corrected visual acuity, closure of the macular hole, continuity of the external limiting membrane, and ellipsoid zone integrity were compared between the two groups during the postoperative follow-up.Results:There was no significant difference in the best corrected visual acuity, the rate of visual acuity improvement, or the rate of macular hole closure between the two groups (all P > 0.05). However, the continuity rate of the external limiting membrane [54.5% (12/22)] and the rate of ellipsoid band integrity [36.4% (8/22)] in the VTM group were significantly higher than those in the non-VTM group [9.1% (2/22), 0; χ2 = 10.47, 7.49, both P < 0.05]. Conclusions:Macular holes caused by VMT show better outcomes after vitrectomy to relieve the vitreous traction. However, for macular holes without remarkable VMT, vitrectomy alone may not yield ideal results. In such cases, it may be necessary to expand the area of ILM removal to adequately relieve the tangential traction.

Pregnancy ; Female ; Humans ; Pre-Eclampsia/epidemiology* ; Prenatal Exposure Delayed Effects ; Case-Control Studies ; China/epidemiology* ; Fluorocarbons/toxicity*